Role of angiotensin converting enzyme inhibitors and angiotensin receptor blockers in hypertension of chronic kidney disease and renoprotection. study results

Hippokratia

Volumn 15, Issue SUPPL. 1, 2011, Pages 27-32

  Baltatzi, M ^a   Savopoulos, Ch ^a   Hatzitolios, A ^a  

^a ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

Author keywords

ACEIs; ARBs; Hypertension; RAAS; Renal disease

Indexed keywords

AMLODIPINE; ANGIOTENSIN II; ANGIOTENSIN RECEPTOR ANTAGONIST; ATENOLOL; BENAZEPRIL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CANDESARTAN; CILAZAPRIL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; HYDROCHLOROTHIAZIDE; IRBESARTAN; LISINOPRIL; LOSARTAN; METOPROLOL; OLMESARTAN; PLACEBO; RAMIPRIL; TELMISARTAN; THIAZIDE DIURETIC AGENT; TRANDOLAPRIL; VALSARTAN;

ALBUMINURIA; ANTIHYPERTENSIVE ACTIVITY; ATHEROSCLEROSIS; BLOOD PRESSURE REGULATION; CHRONIC KIDNEY DISEASE; DIABETIC NEPHROPATHY; DISEASE COURSE; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; HUMAN; HYPERTENSION; HYPOTENSION; KIDNEY FAILURE; KIDNEY FUNCTION; KIDNEY INJURY; MICROALBUMINURIA; MONOTHERAPY; MORBIDITY; MORTALITY; NEPHROSCLEROSIS; NONHUMAN; PATHOPHYSIOLOGY; PROTEINURIA; RENAL PROTECTION; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW;

EID: 79952477482     PISSN: 11084189     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (62)

1. Johnson CA, Levey AS, Coresh J, Levin A, Lau J, Eknoyan G. Clinical practice guidelines for chronic kidney disease in adults;Part I. Definition, disease stages, evaluation, treatment and risk factors. Am Fam Physician 2004; 70: 869-876.
2. Rao M, Qiu, Wang C, Bakris G. Hypertension and CKD: Kidney Early Evaluation Program (KEEP) and National Health and Nutrition Examination Survey (NHANES), 1999-2004. Am J Kidney Dis 2008; 51: S30-S37.
3. Foley RN, Collins AJ. End-stage renal disease in the United States: an update from the United States Renal Data System. J Am Soc Nephrol 2007; 18: 2644-2648.
4. Remuzzi G, Benigni A, Remuzzi A. Mechanisms of progression and regression of renal lesions of chronic nephropathies and diabetes. J Clin Invest 2006; 116: 288-296.
5. Ruster C, Wolf G. Renin-Angiotensin-Aldosterone System and Progression of Renal Disease.J Am Soc Nephrol 2006; 17:2985-2991.
6. Wolf G, Butzmann U, Wenzel UO: The renin-angiotensin system and progression or renal disease: From hemodynamics to cell biology. Nephron Physiol 2003; 93: 3-13.
7. Albiston AL, McDowall SG, Matsacos D, Sim P, Clune E, Mustafa T,et al. Evidence that the angiotensin IV (AT(4)) receptor is the enzyme insulin-regulated aminopeptidase. J Biol Chem 2001; 276: 48623-48626.
8. Nishiyama A, Seth DM, Navar LG: Renal interstitial fluid I and angiotensin II concentrations during local angiotensin converting enzyme inhibition. J Am Soc Nephrol 2002; 13: 2207-2212.
9. Sharma K, Cook A, Smith M, Valancius C, Inscho EW: TGFbeta impairs renal autoregulation via generation of ROS. Am J Physiol Renal Physiol 2005; 288: F1069-F1077.
10. Chen S, Lee JS, Iglesias-de la Cruz MC, Kasama Y, Izquierdo- Lahuerta A, Wolf G, Ziyadeh FN: Angiotensin II stimulates alpha3(IV) collagen production in mouse podocytes via TGFbeta and VEGF signaling: Implications for diabetic nephropathy. Nephrol Dial Transplant 2005; 20: 1320-1328.
11. Sarnak MJ, Levey AS, Schoolwerth AC, Coresh J, Culleton B, Hamm LL, et al. Kidney disease as a risk factor for development of cardiovascular disease: a statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology and Epidimiology and Prevention. Circulation 2003; 108: 2154-2169.
12. MacMahon S, Chalmers J. Blood pressure lowering and ACE inhibition for the avoidance of cardiac and cerebral events. Eur Heart J 2003; 24: 391-393.
13. Law MR, Wald NJ, Morris JK, Jordan RE. Value of low dose combination treatment with blood pressure lowering drugs: analysis of 354 randomised trials. BMJ. 2003; 326: 1427-1431.
14. Matchar DB, McCrory DC, Orlando LA, Patel MR, Patel UD, Patwardhan MB, et al. Systematic review: comparative effectiveness of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers for treating essential hypertension. Ann Intern Med 2008; 148: 16-29.
15. Jennings DL, Kalus JS, Coleman CI, Manierski C, Yee J. Combination therapy with an ACE inhibitor and an angiotensin receptor blocker for diabetic nephropathy: A meta-analysis. Diabet Med 2007; 24: 486-493.
16. Doulton TW, He FJ, MacGregor GA. Systematic review of combined angiotensin-converting enzyme inhibition and angiotensin receptor blockade in hypertension.Hypertension 2005; 45: 880-886.
17. Arύvύ M, Erdem Y. Dual Blockade of the Renin-Angiotensin System for Cardiorenal Protection: An Update. Am J Kidney Dis 2009; 53: 332-345.
18. Takai S, Jin D, Sakaguchi M, Muramatsu M, Miyazaki M. The regressive effect of an angiotensin II receptor blocker on formed fatty streaks in monkeys fed a high cholesterol diet. J Hypertens 2005; 23: 1879-1886.
19. Becker RH, Wiemer G, Linz W. Preservation of endothelial function by ramipril in rabbits on a long-term atherogenic diet. J Cardiovasc Pharmacol 1991; 18: S110-115.
20. Chobanian AV, Haudenschild CC, Nickerson C, Drago R. Antiatherogenic effect of captopril in the Watabnabe heritable hyperlipidaemic rabbit. Hypertension 1990; 15: 327-331
21. Aberg G, Ferrer P. Effects of captopril on atherosclerosis in Cynomolgus monkeys. J Cardiovasc Pharmacol 1990; 15: S65-S72
22. Ridker PM, Danielson E, Rifai N, Glynn RJ. Val-MARC Investigators. Valsartan, blood pressure reduction, and C-reactive protein: primary report of the Val-MARC trial.Hypertension 2006; 48: 73-79.
23. Fliser D, Buchholz K, Haller H. Antiinflammatory effects of angiotensin II subtype 1 receptor blockade in hypertensive patients with microinflammation. Circulation 2004; 31: 1103-1107.
24. Fliser D, Wagner KK, Loos A, Tsikas D, Haller H. Chronic angiotensin II receptor blockade reduces (intra)renal vascular resistance in patients with type 2 diabetes.J Am Soc Nephrol 2005; 16: 1135-1140.
25. Renke M, Tylicki L, Knap N, Rutkowski P, Neuwelt A, Petranyuk A, et al. High-dose angiotensin-converting enzyme inhibitor attenuates oxidative stress in patients with chronic kidney disease. Nephrol Dial Transplant 2009; 24: 689-90.
26. Kunz R, Friedrich C, Wolbers M, Mann J. Meta-analysis: Effect of Monotherapy and Combination Therapy with Inhibitors of the Renin-Angiotensin System on Proteinuria inRenal Disease Ann Intern Med 2008; 148: 30-48.
27. Viberti G, Wheeldon NM. MicroAlbuminuria Reduction With VALsartan (MARVAL) Study Investigators. Microalbuminuria reduction with valsartan in patients with type 2 diabetes mellitus: a blood pressure-independent effect. Circulation 2002; 106: 672-678.
28. Ibsen H, Wachtell K, Olsen MH, Borch-Johnsen K, Lindholm LH, Mogensen CE, et al. Does albuminuria predict cardiovascular outcome on treatment with losartan versus atenolol in hypertension with left ventricular hypertrophy? A LIFE substudy. J Hypertens 2004; 22: 1805-1811.
29. Heart Outcomes Prevention Evaluation Study Investigators. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Lancet 2000; 355: 253-259.
30. Ruggenenti P, Perna A, Ganeva M, Ene-Iordache B, Remuzzi G; BENEDICT Study Group Impact of blood pressure control and angiotensin-converting enzyme inhibitor therapy on newonset microalbuminuria in type 2 diabetes: a post hoc analysis of the BENEDICT trial. J Am Soc Nephrol 2006; 17: 3472-3481.
31. Parving HH, Lehnert H, Bröchner-Mortensen J, Gomis R, Andersen S, Arner P. Irbesartan in Patients with Type 2 Diabetes and Microalbuminuria Study Group. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med 2001; 345: 870-878
32. De Zeeuw D, Remuzzi G, Parving HH, Keane WF, Zhang Z, Shahinfar S, et al. Proteinuria, a target for renoprotection in patients with type 2 diabetic nephropathy: lessons from RENAAL. Kidney Int 2004; 65: 2309-2320.
33. Lea J, Greene T, Hebert L, Lipkowitz M, Massry S, Middleton J, et al. The relationship between magnitude of proteinuria reduction and risk of end-stage renal disease: results of the African American study of kidney disease and hypertension. Arch Intern Med 2005; 165: 947-953.
34. Atkins RC, Briganti EM, Lewis JB, Hunsicker LG, Braden G, Champion de Crespigny PJ, et al. Proteinuria reduction and progression to renal failure in patients with type 2 diabetes mellitus and overt nephropathy. Am J Kidney Dis 2005; 45: 281-287.
35. Hannedouche T, Landais P, Goldfarb B, el Esper N, Fournier A, Godin M, et al. Randomised controlled trial of enalapril and beta blockers in non-diabetic chronic renal failure. BMJ 1994; 309: 833-837.
36. Maschio G, Alberti D, Locatelli F, Mann JF, Motolese M, Ponticelli C, et al. Angiotensin-converting enzyme inhibitors and kidney protection: the AIPRI trial. The ACE Inhibition in Progressive Renal Insufficiency (AIPRI) Study Group.Cardiovasc Pharmacol 1999; 33: 16-20.
37. Ruggenenti P, Perna A, Gherardi G, Gaspari F, Benini R, Remuzzi G. Renal function and requirement for dialysis in chronic nephropathy patients on long-term ramipril: REIN follow-up trial. Gruppo Italiano di Studi Epidemiologici in Nefrologia (GISEN). Ramipril Efficacy in Nephropathy. Lancet 1998; 352: 1252-1256.
38. Ruggenenti P, Perna A, Loriga G, Ganeva M, Ene-Iordache B, Turturro M, et al. Blood-pressure control for renoprotection in patients with non-diabetic chronic renal disease (REIN-2): multicentre, randomised controlled trial.Lancet 2005; 365: 939-946.
39. Hou FF, Zhang X, Zhang GH, Xie D, Chen PY, Zhang WR,et al. Efficacy and safety of benazepril for advanced chronic renal insufficiency. N Engl J Med 2006; 354: 131-140.
40. Wright JT Jr, Bakris G, Greene T, Agodoa LY, Appel LJ, Charleston J, et al. Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: results from the AASK trial. JAMA 2002; 288: 2421-2431.
41. Jafar TH, Stark PC, Schmid CH, Landa M, Maschio G, Marcantoni C, et al. Proteinuria as a modifiable risk factor for the progression of non-diabetic renal disease. Kidney Int 2001; 60: 1131-1140.
42. Lewis EJ, Hunsicker LG, Bain RP, Rohde RD. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group.N Engl J Med 1993; 329: 1456-1462.
43. Bakris GL, Copley JB, Vicknair N, Sadler R, Leurgans S. Calcium channel blockers versus other antihypertensive therapies on progression of NIDDM associated nephropathy. Kidney Int 1996; 50: 1641-1650.
44. Brenner BM, Cooper ME, de Zeeuw D, Keane WF, Mitch WE, Parving HH, et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001; 345: 861-9.
45. Sarafidis PA, Stafylas PC, Kanaki AI, Lasaridis AN Effects of renin-angiotensin system blockers on renal outcomes and allcause mortality in patients with diabetic nephropathy: an updated meta-analysis. Am J Hypertens 2008; 21: 922-929.
46. Black HR, Davis B, Barzilay J, Nwachuku C, Baimbridge C, Marginean H,et al. Metabolic and clinical outcomes in nondiabetic individuals with the metabolic syndrome assigned to chlorthalidone, amlodipine, or lisinopril as initial treatment for hypertension: a report from the Antihypertensive and Lipid- Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Diabetes Care 2008; 31: 353-60.
47. Mann JFE, Schmieder RE, Dyal L, McQueen MJ, Schumacher H, Pogue J, et al. Effect of telmisartan on renal outcomes: a randomized trial. Ann Intern Med 2009; 151: 1-10.
48. Haynes R, Mason P, Rahimi K, Martin J. Landray. Dual blockade of the renin-angiotensin system: are two betterthan one? Nephrol Dial Transplant 2009; 1-6.
49. Jones CA, Krolewski AS, Rogus J, Xue JL, Collins A, Warram JH. Epidemic of end-stage renal disease in people with diabetes in the United States population: do we know the cause? Kidney Int 2005; 67: 1684-1691.
50. Onuigbo M. Reno-prevention vs. reno-protection: a critical reappraisal of the evidence-base from the large RAAS blockade trials after ontarget-a call for more circumspection. Q J Med 2009; 102: 155-167.
51. Suissa S, Hutchinson T, Brophy JM, Kezouh A. ACE-inhibitor use and the long-term risk of renal failure in diabetes. Kidney Int 2006; 69:913-919.
52. Svensson P, de Faire U, Sleight P, Yusuf S, Ostergren J. Comparative effects of ramipril on ambulatory and office blood pressures. A HOPE substudy. Hypertension 2001; 38: e28-32.
53. Mogensen CE, Neldam S, Tikkanen I, Oren S, Viskoper R, Watts RW, Cooper ME.: Randomised controlled trial of dual blockade of renin-angiotensin system in patients with hypertension, microalbuminuria, and non-insulin dependent diabetes: the candesartan and lisinopril microalbuminuria (CALM) study. BMJ 2000; 321:1440-1444.
54. Andersen NH, Poulsen PL, Knudsen ST, Poulsen SH, Eiskjaer H, Hansen KW, et al: Longterm dual blockade with candesartan and lisinopril in hypertensive patients with diabetes. Diabetes Care 2005; 28: 273-277.
55. Doulton TW, He FJ, MacGregor GA. Systematic review of combined angiotensin-converting enzyme inhibition and angiotensin receptor blockade in hypertension. Hypertension 2005; 45: 880-886.
56. MacKinnon M, Shurraw S, Akbari A, Knoll GA, Jaffey J, Clark HD: Combination therapy with an angiotensin receptor blocker and an ACE inhibitor in proteinuric renal disease: a systematic review of the efficacy and safety data. Am J Kidney Dis 2006; 48: 8-20.
57. Catapano F, Chiodini P, De Nicola L, Minutolo R, Zamboli P, Gallo C, Conte G. Antiproteinuric response to dual blockade of the renin-angiotensin system in primary glomerulonephritis: meta-analysis and metaregression.Am J Kidney Dis 2008; 52: 475-485.
58. Bakris GL, Ruilope L, Locatelli F, et al: Treatment of microalbuminuria in hypertensive subjects with elevated cardiovascular risk: results of the IMPROVE trial. Kidney Int 2007; 72: 879-885.
59. Menne J, Farsang C, Deak L, Klebs S, Meier M, Handrock R, et al: Valsartan in combination with lisinopril versus the respective high dose monotherapies in hypertensive patients with microalbuminuria: the VALERIA trial. J Hypertens 2008; 26: 1860-1867.
60. Mann JFE, Schmieder R, McQueen M, Schumacher H, Pogue J, Wang X, et al: Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial. Lancet 2008; 372: 547-553.
61. Khan NA, Hemmelgarn B, Padwal R, Larochelle P, Mahon JL, Lewanczuk RZ,et al; Canadian Hypertension Education Program. The 2007 Canadian Hypertension Education Program recommendations for the management of hypertension: part 2 - therapy. Can J Cardiol 2007; 23: 539-550.
62. Mancia G, De Backer G, Dominiczak A, Cifkova R, Fagard R, Germano G, et al. 2007 ESH-ESC Practice Guidelines for the Management of Arterial Hypertension: ESH-ESC Task Force on the Management of Arterial Hypertension. J Hypertens. 2007; 25: 1751-1762.